Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 75% Improvement Relative Risk Mortality (b) 44% c19hcq.com Stricker et al. HCQ for COVID-19 META ANALYSIS Favors HCQ Favors control
Stricker, 7,616 patient HCQ meta analysis: 75% lower mortality [p<0.0001] https://c19p.org/stricker
copied to clipboard
Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-Analysis
Stricker et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.001 (meta analysis)
5 Aug 2021    Source   PDF   Share   Tweet
Meta analysis of 11 HCQ PrEP studies in India covering 7,616 healthcare workers, showing significantly lower cases with treatment.
Currently there are 38 HCQ for COVID-19 early treatment studies, showing 72% [54‑83%] lower mortality and 41% [28‑52%] lower hospitalization.
risk of death, 75.0% lower, RR 0.25, p < 0.001, treatment 1,273, control 4,127, >=6 doses.
risk of death, 44.0% lower, RR 0.56, p = 0.004, treatment 3,489, control 4,127, any number of doses.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Stricker et al., 8/5/2021, peer-reviewed, 2 authors.
All Studies   Meta Analysis
This PaperHCQAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit